Company / PP&E (Net)
AMICUS THERAPEUTICS, INC. PP&E (Net) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$27.1M
FY2025
5-year range
$27.1M / $42.5M
FY2021-FY2025
Trend
-7.7%
vs FY2024
Sector context
#73 of 193
Health Care
What the data says
At $27M, AMICUS THERAPEUTICS, INC.'s pp&e (net) ranks #73 of 193 in the Health Care sector. PP&E (Net) has fluctuated over the past 10 years, ranging from $9M in FY2017 to $48M in FY2019.
Based on SEC 10-K filings.
$27M in FY2025 with a 5-year CAGR of -9.2%.
Declined from $32M to $27M over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -4.1%
- 5-Year CAGR
- -9.2%
- 10-Year CAGR
- -
Sector benchmark
#73 of 193 in Health CareTop 38% of 193This company $27.1M Sector average $777.6M
▼
-96.5% below sector average
Key checks
Key Insights
- 5-year CAGR of -9.2%, indicating a declining trend.
- In FY2025, pp&e (net) decreased 7.7% year-over-year.
- Ranks #73 out of 193 companies in the Health Care sector.
- Peak pp&e (net) was recorded in FY2019.
Company context
Key Data Points
- Altman Z-Score -1.19 (distress zone, below 1.8 threshold)
- Negative profit margin: -10.6%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $27.1M | -7.7% |
| FY2024 | $29.4M | -7.2% |
| FY2023 | $31.7M | +2.9% |
| FY2022 | $30.8M | -27.6% |
| FY2021 | $42.5M | -3.1% |
| FY2020 | $43.9M | -8.1% |
| FY2019 | $47.7M | +319.4% |
| FY2018 | $11.4M | +25.5% |
| FY2017 | $9.1M | -7.7% |
| FY2016 | $9.8M | +58.9% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026